Latest Biotech News

Emerging technologies continue to reshape biotechnology R&D and diagnostics. Researchers at Oregon Health & Science University developed OmicsTweezer, an AI-powered machine learning tool...

Gene therapy programs face pivotal moments as safety concerns arise. Sarepta’s multiple deaths linked to its Duchenne and limb-girdle muscular dystrophy gene therapies have drawn FDA action and...

The US life sciences workforce shows signs of slowing growth with a modest contraction in hiring during 2024 and early 2025. Despite this, companies continue investing in talent development and...

Regulatory environments continue to evolve, impacting clinical trial ecosystems and product labeling. The European pharmaceutical industry coalition urged swift implementation of the new EU Life...

Sarepta Therapeutics is confronting regulatory challenges after the FDA decided to request a halt on shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following the deaths...

A third patient receiving Sarepta's gene therapy for limb-girdle muscular dystrophy died from acute liver failure, intensifying safety concerns around the company’s gene therapy portfolio. This...

Amid financial pressures and regulatory challenges linked to its gene therapy programs, Sarepta Therapeutics announced a strategic restructuring to reduce annual operating costs by approximately...

The FDA’s Oncologic Drugs Advisory Committee voted against GSK’s application to reintroduce Blenrep, its antibody-drug conjugate for multiple myeloma, citing safety and clinical trial concerns....

Scipher Medicine, known for its molecular assay supporting rheumatoid arthritis treatment decisions, announced a strategic expansion into data-driven precision medicine and drug discovery across...

Biopharmaceutical companies are beginning to explore quantum computing for solving complex research problems that are intractable with classical methods. This nascent technology holds promise for...

Despite a challenging capital environment, early-stage biotech venture financing showed resilience in the first half of 2025. Seed and Series A rounds increased compared to the previous year,...

The biotechnology, pharmaceutical and medical device sectors are witnessing significant activity on public and private capital markets. Hong Kong is an active venue, with 36 life science...

Johnson & Johnson posted a strong second quarter, with med-tech divisions notably outperforming expectations. The company recorded a 6.9% increase in overall sales, led by a 22.3% surge in...

Sarepta Therapeutics faces intensified scrutiny after the FDA requested the halt of its Duchenne muscular dystrophy gene therapy, Elevidys, following two patient deaths from acute liver failure....

Scipher Medicine is broadening its precision medicine efforts beyond diagnostics. After leadership changes, the company is leveraging its extensive collection of non-oncology transcriptomic data...

GSK’s antibody-drug conjugate Blenrep faced setbacks as the FDA’s Oncologic Drugs Advisory Committee voted against its relapsed multiple myeloma label expansion. Concerns raised include...

The U.S. FDA approved 22 drugs in June 2025, tying with March for the highest monthly total this year and contributing to 107 drugs approved in H1 2025. Notable approvals include Gilead’s...

The U.S. life sciences job market report indicates a modest contraction with slight hiring declines in 2024 after years of strong growth. During 2023 and 2024, slowdowns in wage increases and a...

Sarepta Therapeutics announced a comprehensive restructuring marked by approximately 500 layoffs (a 36% workforce reduction) as part of a $400 million annual cost-saving initiative. The plan...

10x Genomics and Singapore's A*STAR Genome Institute launched the TISHUMAP project, leveraging 10x’s Xenium spatial transcriptomics platform combined with advanced AI to analyze up to 2,500...